8-K current report · filed Oct 20, 2026

Arcus Biosciences, Inc. (RCUS) 8-K Current Report: October 20, 2026

Item 8.01RCUS overview

Short answer

Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 8.01 (Other Events). Casdatifan plus zimberelimab delivered 50% cORR and 69% 12-month PFS in first-line ccRCC.

Arcus Biosciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Casdatifan plus zimberelimab delivered 50% cORR and 69% 12-month PFS in first-line ccRCC
  • Casdatifan, ipilimumab and zimberelimab showed 4% primary progression after three months’ follow-up
  • Second-line casdatifan plus cabozantinib produced 14.5-month median PFS and 44% cORR
  • Late-line casdatifan monotherapy achieved 35-month median overall survival and 36% cORR
  • Consistent safety findings across regimens support continued clinical development in ccRCC

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arcus Biosciences, Inc. 8-K filings

Get the next RCUS 8-K as it lands

Follow RCUS for push alerts, or ask the research agent what this filing means.